pharmacology of semaglutide Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? does semaglutide interact with other

May 2010;17(6):389-96

PMID 42464425

Consult with your healthcare provider or registered dietitian for personalized advice tailored to your specific condition

Fatima Cody Stanford, M.D., an obesity medicine physician at Massachusetts General Hospital and associate professor at Harvard Medical School

The findings indicate that: 67% of Omada members were persistent on their medication at one year and experienced weight loss comparable to clinical trials Average weight loss at one year in the program was 18.4% for members persistent on medication and 13.1% for members who discontinued before one year In terms of engagement, members completed more than 10 actions a week on average This data suggests that providing the right kind of support to promote GLP-1 persistence can help patients achieve clinical trial-level weight loss, setting the stage for cardiometabolic disease risk reduction